The titration period: To minimize digestive side effects, doctors typically start with a low dose and gradually increase it over several months
But he said he is also concerned about the fact that, for compounders, its challenging to get the right ingredients. And, as a result, human beings are injecting themselves with versions of GLP-1 drugs meant for laboratory studies, which, Aggarwal said, could be harmful. At the end of the day, these are real humans we are taking care of, he said
In addition, some aspects of GLP-1 beyond weight loss, such as preclinical evidence on GLP-1 effects in directly modulating the hypothalamuspituitarygonadal axis, or the effects of GLP-1RA on clinical and biochemical expression of hyperandrogenism, still deserve a greater insight, especially in light of a possible therapeutic use in PCOS women independently of obesity
Emerging Post-Bariatric Hypoglycemia Competitive Landscape The pipeline for Post-Bariatric Hypoglycemia remains limited, with no approved pharmacological therapies currently available